Cargando…

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response

Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle. Recent advances in the identification of PARPi resistance mechanisms have yielded a better under...

Descripción completa

Detalles Bibliográficos
Autores principales:	Francica, Paola, Rottenberg, Sven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309079/ https://www.ncbi.nlm.nih.gov/pubmed/30593284 http://dx.doi.org/10.1186/s13073-018-0612-8

Ejemplares similares

Meiotic Genes and DNA Double Strand Break Repair in Cancer
por: Lingg, Lea, et al.
Publicado: (2022)

Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors
por: Piombino, Claudia, et al.
Publicado: (2022)

PARP inhibition in breast cancer: progress made and future hopes
por: Tung, Nadine, et al.
Publicado: (2022)

NADP(+) is an endogenous PARP inhibitor in DNA damage response and tumor suppression
por: Bian, Chunjing, et al.
Publicado: (2019)

Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers
por: Liptay, Martin, et al.
Publicado: (2020)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
por: Kim, Chiho, et al.
Publicado: (2020)

A model of DNA damage response activation at stalled replication forks by SPRTN
por: Bruhn, Christopher, et al.
Publicado: (2019)

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures
por: McNevin, Ciara S., et al.
Publicado: (2022)

Introducing the 3(rd) Annual PARP and DNA Damage Response Inhibitors Summit
Publicado: (2020)

Cell-free DNA sequencing sheds additional insights on BRCA-altered metastatic castration-resistant prostate cancer
por: Bazyar, Soha, et al.
Publicado: (2023)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo
por: Shao, Zhengping, et al.
Publicado: (2020)

PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF- кB pathway activity and DNA damage response induced by Idarubicin : PARP-1 inhibitors attenuate DNA damage response
por: Ke, Bo, et al.
Publicado: (2021)

Co-selected mutations in VCP: a novel mechanism of resistance to VCP inhibitors
por: Bastola, Prabhakar, et al.
Publicado: (2018)

PARP inhibitor re-sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis
por: Wu, Jie, et al.
Publicado: (2019)

A two-step mechanism governing PARP1-DNA retention by PARP inhibitors
por: Xue, Huijun, et al.
Publicado: (2022)

PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
por: Jiang, Xuan, et al.
Publicado: (2019)

Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment
por: Jackson, Lindsey M, et al.
Publicado: (2022)

LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors
por: Wang, Yi-Shu, et al.
Publicado: (2016)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC
por: Ciccolini, Joseph, et al.
Publicado: (2020)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
por: Park, Hye Jeong, et al.
Publicado: (2018)

Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity
por: Horton, Julie K., et al.
Publicado: (2013)

Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer
por: Gout, Johann, et al.
Publicado: (2021)

PARP inhibitor resistance: the underlying mechanisms and clinical implications
por: Li, He, et al.
Publicado: (2020)

Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
por: Mweempwa, Angela, et al.
Publicado: (2019)

Mechanism of PARP inhibitor resistance and potential overcoming strategies
por: Fu, Xiaoyu, et al.
Publicado: (2023)

Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer
por: Boerner, Julie L., et al.
Publicado: (2015)

PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies
por: Carter, Jack, et al.
Publicado: (2023)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

[(18)F]AZD2461, an Insight on Difference in PARP Binding Profiles for DNA Damage Response PET Imaging
por: Guibbal, Florian, et al.
Publicado: (2020)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
por: Wang, Nannan, et al.
Publicado: (2022)

The DNA60IFX contest
por: Schatz, Michael C, et al.
Publicado: (2013)

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
por: Kanakkanthara, Arun, et al.
Publicado: (2022)

Comment on Küppers et al. Percutaneous Anorectoplasty (PARP)—An Adaptable, Minimal-Invasive Technique for Anorectal Malformation Repair. Children 2022, 9, 587
por: Peña, Alberto
Publicado: (2022)

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
por: Langelier, Marie-France, et al.
Publicado: (2023)

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
por: Lim, Joline S. J., et al.
Publicado: (2017)

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
por: Rose, Maddison, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p3vr36da173nrv7clp05r6qlu4